Related Experiment Video
Updated: May 13, 2026
06:30
Intraductal Delivery to the Rabbit Mammary Gland
Published on: March 9, 2017
Ductal carcinoma in situ
1Department of Surgical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Room C-308, Philadelphia, PA 19111, USA. richard.bleicher@fccc.edu
The Surgical Clinics of North America
|March 8, 2013
Summary
Management of ductal carcinoma in situ (DCIS) now offers breast-conserving surgery as a minimally invasive option. Radiotherapy remains standard for DCIS treatment, while tamoxifen is standard for receptor-positive disease.
Area of Science:
- Oncology
- Surgical Oncology
- Radiation Oncology
Background:
- Ductal carcinoma in situ (DCIS) management has shifted towards less invasive surgical options.
- Breast conservation surgery (BCS) with radiotherapy is a feasible and safe alternative to mastectomy for DCIS.
Purpose of the Study:
- To review current management strategies for DCIS.
- To discuss the role of radiotherapy and adjuvant therapies in DCIS treatment.
Main Methods:
- Review of current clinical data and treatment guidelines for DCIS.
- Analysis of the efficacy and safety of surgical and non-surgical interventions.
Main Results:
- Breast conservation surgery with radiotherapy is comparable to mastectomy in safety and feasibility.
- Radiotherapy remains the standard of care for BCS in DCIS due to conflicting data on its elimination.
- Tamoxifen significantly reduces recurrence in receptor-positive DCIS and is standard adjuvant therapy.
Conclusions:
- Current DCIS management emphasizes breast conservation surgery, often combined with radiotherapy.
- Adjuvant tamoxifen is a standard treatment for receptor-positive DCIS.
- Ongoing investigations explore novel agents like anastrazole and trastuzumab for DCIS treatment.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
01:24Cellular Adaptation IV: Dysplasia and Metaplasia
DysplasiaDysplasia refers to abnormal changes in the size, shape, and organization of mature cells, characterized by pleomorphism, nuclear abnormalities, and increased mitotic activity. It commonly affects epithelial tissues, including the cervix, gastrointestinal tract, respiratory mucosa, and endometrium. Although it may occur alongside hyperplasia, dysplasia is not a true adaptive response but a preneoplastic change with potential to progress to cancer.When confined above the basement...